The US President, Donald Trump, announced that drugs imported into the United States will not be charged any tariff for two years. Following this,100% tariff will be levied for one year period and 200% later. In a post on Truth Social, Trump said, “all Generic Drugs being brought into the United States will continue to have a TARIFF of ZERO PERCENT for a two year period of time, after which the TARIFF will be raised to 100% for a one year period of time, and 200% thereafter. This is done in order to RESHORE Generic Pharmaceutical Production into America, with a penalty to those Companies that decide not to build Plant and Equipment within the stated period of time given to them.” Pharma stocks will remain in focus.Maruti Suzuki India Ltd has announced a fresh price hike of up to Rs 30,000 across its vehicle portfolio, citing persistent inflationary pressures and a challenging cost environment. The revised prices will come into effect from August 2026, with the exact increase varying across models and variants, the company said in a regulatory filing.Purple Finance Ltd has granted in-principle approval for the proposed acquisition of a 100% equity stake in Saksham Gram Credit Private Limited. The announcement marks a strategic move by Purple Finance to expand its retail lending footprint and distribution capabilities across rural and semi-urban India. The final cost of acquisition, valuation, structure, and payment terms (whether cash consideration or share swap) are currently under discussion and will be finalized upon execution of definitive agreements.Anant Raj Limited has announced a landmark proposal for strategic restructuring with the approval of a Composite Scheme of Arrangement by its Board of Directors. Under the proposed arrangement, Anant Raj will first consolidate all its data centre and cloud operations under one entity before carving them out into Ashok Cloud Pvt Limited, a dedicated digital infrastructure and cloud services company that will be listed independently. The restructuring is aimed at creating two focused businesses one in real estate and infrastructure and the other in digital infrastructure allowing each to pursue independent growth strategies, improve operational efficiency and create long-term value for shareholders. Upon the Scheme becoming effective, eligible shareholders of Anant Raj Limited will receive one fully paid-up equity share of face value of ₹2 each in Ashok Cloud Private Limited for every one fully paid-up equity share of face value of ₹2 each held in Anant Raj Limited.Anupam Rasayan India Ltd it has launched open offer to the public shareholders of Bliss GVS Pharma Ltd to acquire up to 2,77,26,848 fully paid-up equity shares, representing 26% of the expanded voting share capital of the company, at an offer price of ₹299 per share. The mandatory open offer is being made by Anupam Rasayan India Ltd, together with Mates Visa Consultancy Private Limited, acting as the person acting in concert (PAC), Earlier, Anupam Rasayan had signed a definitive agreement to acquire a 43.3% to 48.2% stake in Bliss GVS Pharma for up to ₹1,369.51 crPC Jeweller has informed the exchanges that it has successfully cleared and repaid all its outstanding debt under the terms of Settlement Agreement dated September 30, 2024, with respect to 1 more bank. With this successful clearance of debt, the Company has now repaid all the outstanding debt of 5 out of the 14 consortium banks.Zen Technologies Limited has received an order amounting to ₹ 177.5 crores (including GST), for upgradation and integration of Tank and Crew Gunnery Simulators from Ministry of Defence, Government of India.CuraTeQ Biologics Pvt Limited, a wholly owned subsidiary of Aurobindo Pharma Limited, has received approval from ANVISA (Agência Nacional de Vigilância Sanitária), the National Health Surveillance Agency of Brazil, for its biosimilars manufacturing facility in Hyderabad. The facility underwent a GMP inspection by ANVISA from May 11 to May 15, 2026, and the approval was granted following successful completion of the inspection for biological API and sterile products. The scope of the GMP inspection covered four biosimilar products and assessed the mammalian and microbial drug substance manufacturing facility, prefillable syringe and vial filling facility, packaging and labelling facility, QC testing and release laboratories.Published on July 22, 2026